© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Drs Richard D. Carvajal and Marlana M. Orloff describe the rationale for treating uveal melanoma with tebentafusp and provide insight on assessing treatment response and managing treatment-related adverse events.
July 23rd 2021
A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.
Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.
Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.
Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.
August 2nd 2021
Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.
What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.
Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.
Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.
The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.